How does luteolin slow diffuse large B-cell lymphoma?
The flavonoid luteolin inhibited DLBCL cell growth (IC50 ~11–12 μM), drove G2/M arrest and apoptosis, and shrank U2932 xenografts while lowering p-JAK2/p-STAT3.
Source
Luteolin inhibits diffuse large B-cell lymphoma cell growth through the JAK2/STAT3 signaling pathway
Study at a glance
- Design
- Animal / in-vitro — DLBCL cell lines (U2932, OCI-LY10) plus U2932 xenograft nude mice (4 groups × n=5) and JAK2 docking/MD.
- N
- N=20 · In vivo n=5 mice × 4 dose groups (0, 12.5, 25, 50 mg/kg); in vitro two human DLBCL lines.
- Population
- Human DLBCL cell lines U2932 and OCI-LY10 and U2932-bearing nude mice.
- Outcome
- Proliferation IC50, apoptosis, G2/M arrest, xenograft growth, and p-JAK2/p-STAT3 vs total JAK2/STAT3.
Structured fields used in claim comparison tables when every cited study has a complete layer.
What they did
CCK-8, Annexin V, and cell-cycle assays on U2932/OCI-LY10 at 0–20 μM; nude mice with U2932 tumors got 12.5/25/50 mg/kg luteolin IP twice daily for 14 days vs saline; Western blots and JAK2 docking/MD.
What they found
IC50 10.91 μM (U2932) and 12.03 μM (OCI-LY10). Apoptosis at 20 μM reached ~54% (U2932) and ~67% (OCI-LY10). G2/M fractions rose dose-dependently. Xenograft volume/weight fell without much body-weight loss; p-JAK2 and p-STAT3 fell while total JAK2/STAT3 stayed flat; Bax/cleaved caspase-3/PARP1 rose.
The limits
What it doesn't show
No human trial; two cell lines and n=5/group mice; JAK2 binding is computational; clinical DLBCL already has R-CHOP, so luteolin is a candidate mechanism, not a proven therapy.
Key terms
- Luteolin
- Dietary/botanical flavonoid tested here as an anti-DLBCL compound.
- DLBCL
- Diffuse large B-cell lymphoma, an aggressive B-cell cancer.
- JAK2/STAT3
- Kinase–transcription-factor path promoting lymphoma survival; luteolin reduced the phosphorylated forms.
- IC50
- Concentration inhibiting 50% of cell growth (~11–12 μM at 72 h).
- G2/M arrest
- Cell-cycle block before mitosis, increased by luteolin in both lines.
Flashcards
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
U2932 IC50 was about:
Common questions
U2932 IC50?
10.91 μM after 72 h.
Mouse doses?
12.5, 25, and 50 mg/kg IP twice daily for 14 days (n=5/group).
Did total JAK2/STAT3 fall?
No; only phosphorylated JAK2 and STAT3 decreased.
20 μM apoptosis in U2932?
About 53.8%.
More on Oncology outcomes